Barrett's esophagus.
Keywords:
ESÓFAGO DE BARRETT, METAPASIA, CARCINOMAAbstract
Barret's esophagus is an entity not frequently diagnosed in our hospital due to the its hidden symptomatology. Many cases are not discovered but when panendoscopy is developed its number is higler and much higler when necrological studies are carried out. Due to what we have stated, we decided to carry out a bibliographical review about some aspects of this topic.Downloads
Download data is not yet available.
References
1. Shaheen N, Ransohoff DF. Gastroesophageal reflux, Barrett´s esophagus, and esophageal cancer. Clinical applications. JAMA 2002; 287: 1982-1986.
2. Spechler SJ. Columnar-lined esophagus. Definitions. Chest Surg Clin North Am 2002b; 12: 1-13.
3. Mahue-Giangreco M, Bernstein L. Epidemiology of Barrett´s esophagus. Prob Gen Surg 2001; 18: 4-11. Félix Patiño J:
4. Naef AP, Savary M, Ozzello L. Columnar-lined lower esophagus: an acquired lesion with malignant predisposition. J Thorac Cardiovasc Surg 1975; 70: 826-75.
5. Spechler SJ. VA Gastroesophageal Reflux Disease Study Group. Comparison of medical and surgical therapy for complicated gastroesophageal refux disease in veterans. N Engl J Med 1992; 326: 786-92.
6. Smith CD. The esophagus. In: JA Norton, RR Bollinger, AE Chang, SF Lowry, SJ Mylvihill, HI Pass, RW Thompson (Eds). Surgery. Basic Science and Clinical Evidence. New York: Springer-Verlag; 2001. p. 474.
7. Spechler SJ. Barrett´s esophagus. N Engl J Med 2002a; 346: 836-42.
8. Mason RJ. Pathophysiology of Barrett´s esophagus: role of stomach in early disease, lower esophageal sphincter, and esophageal body dysfunction with advancing disease. Prob Gen Surg 2001; 18: 12-7.
9. Peters JH. Pathophysiology of Barrett´s esophagus: role of bile and luminal contents. Prob Gen Surg 2001; 18: 18-26.
10. Melguizo Bermúdez M. Esófago de Barrett y cirugía antirreflujo. Rev Colom Cir 2001; 16:180-4.
11. DeMeester TR. Barrett’s esophagus. Surgery 1993: 113: 239-41.
12. Gelfand MD. Barrett´s esophagus in sexagenarian identical twins. J. Clin. Gastroenterol. 1983, 5 (251-253).
13. Jochem VS, Fuerst PA., Fromkess JJ. Familial Barrett´s esophagus associated with adenocarcinoma. Gastroenterology 1992; 102:1400-1402.
14. Savarino V, Mela GS, Zentilin P. Time pattern of gastric acidity in Barrett´s esophagus. Dig. Dis. Sci. 1996, 41:1379-1383.
15. Liron R., Parrilla P, Martinez De Haro LF. Quantification of duodenogastric reflux in Barrett´s esophagus. Am J Gastroenterol. 1997;92:32-36.
16. Parrilla P, Liron R, Martinez De Haro LF. Gastric surgery does nor increase the risk of developing Barrett´s esophagus. Am J Gastroenterol 1997; 92:960-963.
17. Birgisson S, Rice TW, Easley KA, Richter JE. The lack of association between adenocarcinoma of the esophagus and gastric surgery: a retrospective study. Am J Gastroenterol 1997; 92:216-221.
18. Ferreira EAB, Ferreira FO. Câncer do esÙfago. Clin Brasil Cirur 1996; 2(1):133.
19. Peters JH, DeMeester TR. Carcinoma of the esophagus. En: SI Schwartz, GT Shires, FC Spencer, WC Huser (Eds). Principles of Surgery. 6 ed. New York: McGraw-Hill;1994.
20. Tytgat GNJ. Does endoscopic surveillance in esophageal columnar metaplasia (Barrett´s esophagus) have any real value? Endoscopy 1995; 27:19-26.
21. DeMeester SR, Peters JH, DeMeester TR. Barrett´s esophagus. Curr Prob Surg 2001; 38: 553-40.
22. Crawford JM. Aparato Gastrointestinal. En: Cotran RS, Kumar V, Collins T. Robbins. Patología Estructural y Funcional. 6ta ed. Madrid: Interamericana; 2000.p. 815-6.
23. Flejou JF. What are the histologic criteria that justify claiming the regression of Barrett´s esophagus. In: Giuli R. (Ed). The esophageal mucosa. Amsterdam: Elsevier; 1994. p.958-960.
24. Brand DL, Ylvisaker JT, Gelfand M. Regression of columnar esophageal (Barrett´s) epithelium after anti-reflux surgery. N Engl J Med 1980; 302:844-848.
25. DeMeester SR, DeMeester TR: Columnar mucosa and intestinal metaplasia of the esophagus. Fifty years of controversy. Ann Surg 2000; 231: 303-21.
26. Klinkenberg-Knoll EC, Nelis F, Dent J, Snel P. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety and influence on gastric mucosa. Gastroenterology 2000; 118: 61-9.
27. Malesci A, Savarino V, Zenith P. Partial regression of Barrett´s esophagus by long-term therapy with high-dose omeprazole. Gastrointest Endosc 1996; 44:700-705.
28. García Menéndez A, Vinagreras Barroso J, Tacatic Cáceres B: Terapia de ablación en pacientes con esófago de Barrett utilizando electrocuagulación con argón plasma: Experiencia preliminar en el Hospital Español de México. Endoscopia (México) 1999; 10: 151-4.
29. Oberholt BF, Panjehpour M, Haydeck JM. Photodynamic therapy for Barrett´s esophagus: follow-up in 100 patients. Gastrointest Endosc 1999; 49: 1-7.
30. Bremmer RM, Bremmer CG. Ablation therapy for Barrett´s esophagus. Prob Gen Surg 2001; 18: 85-93.
31. Sampliner RE, Camargo L, Fass R. Impact of esophageal acid exposure on the endoscopic reversal of Barrett´s esophagus. Am J Gastroeneterol 2002; 97: 270-2.
32. Sampliner RE, Fennerty MB, Garewall MD. Reversal of Barrett´s esophagus with acid suppression and multipolar electrocoagulation: preliminary results. Gastrointest Endosc 1996; 44:523-525.
2. Spechler SJ. Columnar-lined esophagus. Definitions. Chest Surg Clin North Am 2002b; 12: 1-13.
3. Mahue-Giangreco M, Bernstein L. Epidemiology of Barrett´s esophagus. Prob Gen Surg 2001; 18: 4-11. Félix Patiño J:
4. Naef AP, Savary M, Ozzello L. Columnar-lined lower esophagus: an acquired lesion with malignant predisposition. J Thorac Cardiovasc Surg 1975; 70: 826-75.
5. Spechler SJ. VA Gastroesophageal Reflux Disease Study Group. Comparison of medical and surgical therapy for complicated gastroesophageal refux disease in veterans. N Engl J Med 1992; 326: 786-92.
6. Smith CD. The esophagus. In: JA Norton, RR Bollinger, AE Chang, SF Lowry, SJ Mylvihill, HI Pass, RW Thompson (Eds). Surgery. Basic Science and Clinical Evidence. New York: Springer-Verlag; 2001. p. 474.
7. Spechler SJ. Barrett´s esophagus. N Engl J Med 2002a; 346: 836-42.
8. Mason RJ. Pathophysiology of Barrett´s esophagus: role of stomach in early disease, lower esophageal sphincter, and esophageal body dysfunction with advancing disease. Prob Gen Surg 2001; 18: 12-7.
9. Peters JH. Pathophysiology of Barrett´s esophagus: role of bile and luminal contents. Prob Gen Surg 2001; 18: 18-26.
10. Melguizo Bermúdez M. Esófago de Barrett y cirugía antirreflujo. Rev Colom Cir 2001; 16:180-4.
11. DeMeester TR. Barrett’s esophagus. Surgery 1993: 113: 239-41.
12. Gelfand MD. Barrett´s esophagus in sexagenarian identical twins. J. Clin. Gastroenterol. 1983, 5 (251-253).
13. Jochem VS, Fuerst PA., Fromkess JJ. Familial Barrett´s esophagus associated with adenocarcinoma. Gastroenterology 1992; 102:1400-1402.
14. Savarino V, Mela GS, Zentilin P. Time pattern of gastric acidity in Barrett´s esophagus. Dig. Dis. Sci. 1996, 41:1379-1383.
15. Liron R., Parrilla P, Martinez De Haro LF. Quantification of duodenogastric reflux in Barrett´s esophagus. Am J Gastroenterol. 1997;92:32-36.
16. Parrilla P, Liron R, Martinez De Haro LF. Gastric surgery does nor increase the risk of developing Barrett´s esophagus. Am J Gastroenterol 1997; 92:960-963.
17. Birgisson S, Rice TW, Easley KA, Richter JE. The lack of association between adenocarcinoma of the esophagus and gastric surgery: a retrospective study. Am J Gastroenterol 1997; 92:216-221.
18. Ferreira EAB, Ferreira FO. Câncer do esÙfago. Clin Brasil Cirur 1996; 2(1):133.
19. Peters JH, DeMeester TR. Carcinoma of the esophagus. En: SI Schwartz, GT Shires, FC Spencer, WC Huser (Eds). Principles of Surgery. 6 ed. New York: McGraw-Hill;1994.
20. Tytgat GNJ. Does endoscopic surveillance in esophageal columnar metaplasia (Barrett´s esophagus) have any real value? Endoscopy 1995; 27:19-26.
21. DeMeester SR, Peters JH, DeMeester TR. Barrett´s esophagus. Curr Prob Surg 2001; 38: 553-40.
22. Crawford JM. Aparato Gastrointestinal. En: Cotran RS, Kumar V, Collins T. Robbins. Patología Estructural y Funcional. 6ta ed. Madrid: Interamericana; 2000.p. 815-6.
23. Flejou JF. What are the histologic criteria that justify claiming the regression of Barrett´s esophagus. In: Giuli R. (Ed). The esophageal mucosa. Amsterdam: Elsevier; 1994. p.958-960.
24. Brand DL, Ylvisaker JT, Gelfand M. Regression of columnar esophageal (Barrett´s) epithelium after anti-reflux surgery. N Engl J Med 1980; 302:844-848.
25. DeMeester SR, DeMeester TR: Columnar mucosa and intestinal metaplasia of the esophagus. Fifty years of controversy. Ann Surg 2000; 231: 303-21.
26. Klinkenberg-Knoll EC, Nelis F, Dent J, Snel P. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety and influence on gastric mucosa. Gastroenterology 2000; 118: 61-9.
27. Malesci A, Savarino V, Zenith P. Partial regression of Barrett´s esophagus by long-term therapy with high-dose omeprazole. Gastrointest Endosc 1996; 44:700-705.
28. García Menéndez A, Vinagreras Barroso J, Tacatic Cáceres B: Terapia de ablación en pacientes con esófago de Barrett utilizando electrocuagulación con argón plasma: Experiencia preliminar en el Hospital Español de México. Endoscopia (México) 1999; 10: 151-4.
29. Oberholt BF, Panjehpour M, Haydeck JM. Photodynamic therapy for Barrett´s esophagus: follow-up in 100 patients. Gastrointest Endosc 1999; 49: 1-7.
30. Bremmer RM, Bremmer CG. Ablation therapy for Barrett´s esophagus. Prob Gen Surg 2001; 18: 85-93.
31. Sampliner RE, Camargo L, Fass R. Impact of esophageal acid exposure on the endoscopic reversal of Barrett´s esophagus. Am J Gastroeneterol 2002; 97: 270-2.
32. Sampliner RE, Fennerty MB, Garewall MD. Reversal of Barrett´s esophagus with acid suppression and multipolar electrocoagulation: preliminary results. Gastrointest Endosc 1996; 44:523-525.
Downloads
How to Cite
1.
Perera Rodríguez LL, Cordero Jiménez CP, de la Paz Granado ME. Barrett’s esophagus. Mediciego [Internet]. 2004 Sep. 22 [cited 2024 Nov. 27];10(2). Available from: https://revmediciego.sld.cu/index.php/mediciego/article/view/2671
Issue
Section
Review article
License
Those authors who have publications with this journal accept the following terms of the License CC Attribution-NonCommercial 4.0 International (CC BY-NC 4.0):
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- NonCommercial — You may not use the material for commercial purposes .
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
